Clinical Trial Update: A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1) [Phase 3]

View source ↗

Summary

Phase 3 AGATE-1 evaluated the safety and efficacy of Ombitasvir/Paritaprevir/Ritonavir with Ribavirin in adults with genotype 4 chronic hepatitis C infection an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis of the Liver
• Hepatitis C

Drugs mentioned

• Ombitasvir (ombitasvir)
• Paritaprevir (paritaprevir)
• Ribavirin (ribavirin)
• Ritonavir (Ritonavir)

Snippet

Sponsor: AbbVie | Conditions: Hepatitis C Virus | Phase 3 | Status: COMPLETED | Results posted: 2017-08-31